<DOC>
	<DOCNO>NCT00105105</DOCNO>
	<brief_summary>The purpose study evaluate effect C-1073 ( Mifepristone ) cognition patient Alzheimer 's disease ( AD ) also take acetylcholinesterase inhibitor ( Aricept , Exelon Reminyl ) .</brief_summary>
	<brief_title>Mifepristone Adjunctive Therapy Alzheimer 's Disease</brief_title>
	<detailed_description>This double blind , placebo control study C-1073 evaluate effect cognition patient mild moderate Alzheimer 's disease already receive acetylcholinesterase inhibitor stable dose least 12 week . Patients randomize ( 1:1 ) either daily dose 300 mg C-1073 placebo 16 week . Patients continue stable daily dose acetylcholinesterase inhibitor throughout study . Visits weekly beginning study , every two week , every 4 week week 12 . Assessments visit may include cognition behavior , depression , safety , well physical exam , clinical laboratory test , EKG adverse event reporting .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Diagnosis Alzheimer 's disease Women must partial complete hysterectomy Mini Mental Status Evaluation score 1827 HAMD score less equal 18 Able provide write informed consent On stable dose acetylcholinesterase inhibitor least 12 week prior screen visit Ambulatory , ambulatory walker cane Sufficient hearing vision enable patient comply study procedure Caregiver available participate assessment patient monitor dose Women intact uterus A clinically significant medical condition , include lab abnormality , opinion investigator would place patient undue risk , would impair patient 's ability participate study . These include limited : history cerebral vascular accident ( CVA ) , adrenal insufficiency , porphyria , autoimmune disorder , type I diabetes , chronic obstructive pulmonary disease ( COPD ) , hematologic oncologic disorder previous 2 year , vitamin B12 folate deficiency A clinically significant active gastrointestinal , renal , hepatic , endocrine , cardiovascular system disease well control diet , pharmacological treatment , therapeutic intervention History psychotic episode bipolar disorder , additional diagnosis delusion , delerium , depression Evidence psychiatric neurologic disorder ( e.g. , stroke , schizophrenia , Parkinson disease ) Hachinski ischemia score 5 Known hypersensitivity cholinesterase inhibitor Use systemic pulmonary inhale corticosteroid within 30 day prior randomization , require use medication study Use memantine ( Namenda ) within 30 day prior randomization , require use medication study Currently take medication know significantly induce inhibit metabolism CYP 3A4 , take medication 7 day prior randomization ( see list prohibited medication ) Use anticholinergic compound within 30 day prior randomization , require use medication study History electroconvulsive therapy ( ECT ) ; patient may undergo ECT course trial Positive urine drug screen nonprescribed drug abuse ( include limit amphetamine , cannabinoids , barbiturate , cocaine , opiates , benzodiazepine ) History illicit drug usage history drug alcohol dependence Known another form dementia may also explain patient 's deficit include reversible dementia , Binswanger 's , Parkinson 's dementia complex , Korsakoff 's , mental retardation vascular dementia . Patients meet clinical criterion AD deep white matter lesion MRI CT scan accept . Currently take prescription anticoagulant warfarin ( Coumadin ) Planned surgical procedure study period , include 4 week drug period week 16 20 Participation clinical investigation drug , biological investigational therapy within 30 day prior dose Previous participation trial use mifepristone , know sensitivity allergy C1073 ( mifepristone ) constituent Body Mass Index ( BMI ) 35 Prohibited Medications : Medications know significantly induce inhibit metabolism CYP 3A4 , specifically : carbamazepine ( Carbatrol® Tegretol® ) modafinil ( Provigil® ) nefazodone ( Serzone® ) droperidol erythromycin fluconazole ( Diflucan® ) itraconazole ( Sporanox® ) ketoconazole ( Nizoral® ) simvastatin ( Zocor® ) lovastatin ( Mevacor® ) vinblastine vincristine paclitaxel ( Taxol® ) tamoxifen ( Nolvadex® ) cyclosporine ( Neoral® , Sandimmune® ) tacrolimus ( Gengraf® ) sirolimus ( Rapamune® ) midazolam ( Versed® ) nicardipine ( Cardene® ) nifedipine ( Adalat® , Procardia® ) felodipine ( Lexxel® , Plendil® ) thioridizine pimozide ( Orap® ) quinidine Patient may also take St. John 's Wort study within 7 day prior study entry use grapefruit juice exclude course study . use anticholinergic compound past 30 day prior randomization warfarin ( Coumadin ) systemic inhaled pulmonary corticosteroid memantine ( Namenda )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Alzheimers</keyword>
	<keyword>cognition</keyword>
	<keyword>acetyl cholinesterase inhibitor</keyword>
	<keyword>GR-II antagonist</keyword>
</DOC>